Inactive Instrument

Biocure Technology Inc. Stock Other OTC

BICTF

CA09075T1075

Latest news about Biocure Technology Inc.

Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
Atriva Therapeutics GmbH announced that it expects to receive $15 million in funding	23-09-17	CI
Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc..	23-09-17	CI
Biocure Technology Inc. announced that it has received $15 million in funding from Atriva Therapeutics GmbH	23-09-17	CI
Biocure Technology Inc. Announces Chief Executive Officer Changes	23-09-08	CI
Biocure Technology Inc. Announces Board of Director Changes	23-09-08	CI
Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Biocure Technology Inc. Announces Resignation of Berkan Unal from its Board of Directors	23-07-05	CI
Sang Mok Lee acquired 46% of stake in BiocurePharm Corporation from Biocure Technology Inc..	23-05-30	CI
Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-28	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-16	CI
Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	23-05-15	CI
Biocure Technology Inc. announced that it has received CAD 0.2376 million in funding	23-01-29	CI
Biocure Technology Inc. announced that it has received CAD 0.0541 million in funding	23-01-16	CI
BiocurePharm Corporation announced that it has received CAD 0.0541 million in funding from Biocure Technology Inc.	23-01-15	CI

More news

Press releases Biocure Technology Inc.

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology	23-09-18	AQ
Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction	23-09-18	NE
Canadian Investment Regulatory Organization Trading Halt - CURE	23-09-14	AQ
Biocure Technology : “CURE”) Announces Resignation of a Director, Appointment of New CEO	23-09-07	PU
Biocure Technology : Clarification News Release	23-02-02	PU

More press releases

Managers and Directors - Biocure Technology Inc.

Managers	Title	Age	Since
Sang-Mok Lee FOU	Founder	58	07-08-23
Konstantin Lichtenwald DFI	Director of Finance/CFO	40	18-02-28
Björn Cochlovius PSD	President	56	21-07-21

Members of the board	Title	Age	Since
Sang-Mok Lee FOU	Founder	58	07-08-23
Konstantin Lichtenwald DFI	Director of Finance/CFO	40	18-02-28
Collin Kim BRD	Director/Board Member	58	15-08-27

More insiders

Biocure Technology Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company is comprised of scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. In addition, the Company is developing Biosimilar technologies for cancer treatment. The Companyâs products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

Sector

Uranium

Calendar

2024-04-30 - Q4 2023 Earnings Release (Projected)

More about the company

Sector Other Uranium

	1st Jan change	Capi.
CAMECO CORPORATION	+17.63%	21.14B
URANIUM ENERGY CORP.	+3.98%	2.68B
CGN MINING COMPANY LIMITED	+17.44%	1.98B
YELLOW CAKE PLC	-0.32%	1.69B
BOSS ENERGY LIMITED	+14.39%	1.22B
CENTRUS ENERGY CORP.	-25.45%	639M
URANIUM ROYALTY CORP.	-13.20%	276M
ELEVATE URANIUM LTD	+5.62%	94.06M
GOVIEX URANIUM INC.	-41.67%	53.3M

Other Uranium

Sales 2021	-	Sales 2022	-	Capitalization	1.09M
Net income 2021	-1M	Net income 2022	-1M	EV / Sales 2021	-
Net Debt 2021	3.63M	Net Debt 2022	43.52K	EV / Sales 2022	-
P/E ratio 2021	-11.9 x	P/E ratio 2022	-0.74 x	Employees	-
Yield 2021 *	-	Yield 2022	-	Free-Float	99.89%

Biocure Technology Inc. Stock Other OTC

Equities